1. We aimed to choose two approaches that were as different as possible to each other to maximise the chance that at least one worked. If we has say settled on running two anti-PD-1 combination trials in say melanoma and lung cancer, then we haven’t really derisked the company. Based on the data we had at the time the programs were chosen we felt melanoma and ccRCC were the two most dissimilar in mechanism of action.
2. Yes and no. I can’t really go into more details than this other than to say that even if Zantrene turns out to not be useful for inducing synthetic lethality in VHL- cancers, it could still prove very useful in combination with other treatments. This is why we are exploring more than just synthetic lethality in the preclinical program.
Pillar 1 - FTO (new thread), page-1773
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |